Lansoprazol Tetrafarma

Lansoprazole, the active ingredient in Lansoprazol Tetrafarma, is a proton pump inhibitor presented as a tablet for oral use. It reduces gastric acid production and is used to treat acid‑related disorders such as gastro‑esophageal reflux disease and peptic ulcer disease in adult patients.

GNH USA supplies Lansoprazol Tetrafarma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansoprazole is indicated for several acid‑related conditions, acting on the gastric proton pump pathway.

- Gastro‑esophageal reflux disease (GERD): alleviates heartburn and reflux symptoms by decreasing acid exposure in the esophagus. - Erosive esophagitis: promotes healing of inflamed esophageal tissue by suppressing gastric acid. - Peptic ulcer disease: facilitates ulcer healing and prevents recurrence through acid reduction. - Helicobacter pylori eradication regimen: enhances the effectiveness of antibiotic therapy by creating a less acidic gastric environment.

Lansoprazole may be associated with a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often transient. - Diarrhea: loose stools that may resolve with continued therapy. - Nausea: occasional queasy sensation. - Abdominal pain: mild discomfort in the stomach area. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reactions (e.g., Stevens‑Johnson syndrome): skin rash, blistering, or mucosal involvement. - Clostridioides difficile infection: severe colitis presenting with watery diarrhea. - Hypomagnesemia: low magnesium levels with prolonged use, causing muscle cramps or arrhythmias. - Bone fracture risk: increased incidence of hip, wrist, or spine fractures with long‑term therapy. - Elevated liver enzymes: signs of hepatic irritation. - Interstitial nephritis: kidney inflammation presenting with reduced urine output or swelling.

When prescribing lansoprazole, clinicians should consider several safety precautions.

- Assess renal function: adjust use in severe renal impairment. - Monitor magnesium levels: prolonged therapy may cause hypomagnesemia. - Evaluate bone health: long‑term use may increase fracture risk. - Check for Helicobacter pylori infection: consider eradication regimen when indicated. - Avoid in known hypersensitivity: discontinue if rash, angioedema, or other allergic signs appear. - Store at room temperature: keep in original container, protect from moisture and heat.

Lansoprazole can affect the plasma concentrations of other medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, potentially increasing cardiovascular risk. - Atazanavir: decreased absorption leading to sub‑therapeutic antiviral levels. - High‑dose methotrexate: increased toxicity due to reduced clearance.

Moderate Interactions (Monitor Closely): - Warfarin: possible INR elevation, requiring closer coagulation monitoring. - Digoxin: increased serum concentrations, may need dose adjustment. - Diazepam: enhanced sedation, monitor CNS effects. - Ketoconazole: reduced antifungal efficacy, consider alternative therapy.